Clinical bottom line
Post-concussion syndrome (PCS) in athletes presents a complex challenge in rehabilitation, with symptoms persisting beyond the typical recovery period. Emerging therapies, including cognitive rehabilitation, vestibular therapy, and novel pharmacological approaches, show promise in managing PCS. However, these therapies require further validation through rigorous clinical trials to establish efficacy and safety in athletic populations.
What the evidence shows
Recent studies have explored various interventions for PCS, focusing on symptom management and functional recovery. Cognitive rehabilitation, which includes memory exercises and attention training, has been shown to improve cognitive symptoms in PCS patients [PMID: 30304642, 2018]. Vestibular therapy, targeting balance and dizziness, has demonstrated efficacy in reducing vestibular symptoms and improving quality of life [PMID: 31039233, 2019]. Additionally, pharmacological interventions, such as the use of amantadine, have been investigated for their potential to alleviate cognitive and mood-related symptoms, although results are mixed and require further study [PMID: 30920963, 2019].
Caveats and uncertainty
While these emerging therapies offer potential benefits, several caveats exist. The heterogeneity of PCS symptoms and the variability in individual responses to treatment complicate the establishment of standardized protocols. Moreover, most studies have small sample sizes and short follow-up periods, limiting the generalizability of findings. The lack of large-scale, randomized controlled trials (RCTs) further underscores the need for cautious interpretation of current evidence. Additionally, the long-term effects and safety of pharmacological treatments remain uncertain, necessitating further investigation.
How this may change practice
The integration of emerging therapies into clinical practice for PCS in athletes could enhance symptom management and expedite return-to-play decisions. Cognitive and vestibular therapies may be incorporated into multidisciplinary rehabilitation programs, offering a more holistic approach to PCS management. However, clinicians should remain vigilant about the limitations of current evidence and continue to rely on established guidelines while considering these novel interventions. Ongoing research and clinical trials will be crucial in refining treatment protocols and ensuring safe, effective care for athletes with PCS.